Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation - Subanalysis of J-ROCKET AF for patients with moderate renal impairment -

Circulation Journal

Volumn 77, Issue 3, 2013, Pages 632-638

  Hori, Masatsugu ^a   Matsumoto, Masayasu ^d   Tanahashi, Norio ^e   Momomura, Shin Ichi ^f   Uchiyama, Shinichiro ^g   Goto, Shinya ^h   Izumi, Tohru ⁱ   Koretsune, Yukihiro ^b   Kajikawa, Mariko ^c   Kato, Masaharu ^c   Ueda, Hitoshi ^c   Iwamoto, Kazuya ^c   Tajiri, Masahiro ^c  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c Bayer Yakuhin   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^h TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrial fibrillation; Renal impairment; Rivaroxaban; Stroke; Warfarin

Indexed keywords

RIVAROXABAN; WARFARIN;

ADULT; AGED; ARTICLE; BACKACHE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTUSION; CREATININE CLEARANCE; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; EPISTAXIS; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SUBCUTANEOUS HEMORRHAGE; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JAPAN; KIDNEY; MALE; MIDDLE AGED; MORPHOLINES; RENAL INSUFFICIENCY; REPRODUCIBILITY OF RESULTS; RISK FACTORS; STROKE; THIOPHENES; TREATMENT OUTCOME; WARFARIN;

EID: 84874404273     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0899     Document Type: Article

References (26)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
3. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
6. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, et al. Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157: 805-810, 810 e1-e2.
7. Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L; RE-LY Investigators. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation: Sub-analysis in Japanese population in RE-LY trial. Circ J 2011; 7: 800-805.
8. Ogawa S, Koretsune Y, Yasaka M, Aizawa Y, Atarashi H, Inoue H, et al. Antithrombotic therapy in atrial fibrillation: Evaluation and positioning of new oral anticoagulant agents. Circ J 2011; 75: 1539-1547.
9. Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008; 24: 2757-2765.
10. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
11. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
12. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
14. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010; 70: 703-712.
15. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: Population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675-686.
16. Tanigawa T, Kaneko M, Hashizume K, Kajikawa M, Ueda H, Tajiri M, et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet 2012 July 17 [Epub ahead of print].
17. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban versus warfarin in Japanese patients with atrial fibrillation. Circ J 2012; 76: 2104-2111.
18. Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008; 51: S13-S20.
19. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363-1369.
20. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33: 1500-1510.
21. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58: 395-401.
22. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093-1100.
23. Vazquez E, Sanchez-Perales C. The HAS-BLED score and renal failure. Chest 2011; 139: 1248-1249; author reply 1249-1250.
24. Ogawa S, Hori M. Urgent statement on antithrombotic therapy of atrial fibrillation. Circ J 2011; 75: 2719-2721.
25. Schirmer SH, Baumhakel M, Neuberger HR, Hohnloser SH, van Gelder IC, Lip GY, et al. Novel anticoagulants for stroke prevention in atrial fibrillation: Current clinical evidence and future developments. J Am Coll Cardiol 2010; 56: 2067-2076.
26. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-2394.